摘要
Triflavin, an Arg-Gly-Asp-containing peptide from Trimeresurus flauoviridis snake venom (M1, of 7500 Da) inhibits platelet aggregation through the blockade of fibrinogen binding to activated platelets. The present study demonstrated that the intravenous injection of triflavin (0.1 and 0.25 mg/kg) significantly prolonged the bleeding time about 1.8- to 2.4-fold as compared with control (normal saline) of severed mesenteric arteries in rats, whereas the injection of Gly-Arg-Gly-Asp-Ser (GRGDS) (2-8 mg/kg) failed to increase the bleeding time in this model. Continuous infusion of triflavin (0.08 mg/kg/min) significantly increased the bleeding time about 2.6-fold, and the bleeding time returned to normal within 20 min after the cessation of triflavin infusion. Triflavin (10-20 mg/kg) significantly prolonged the occlusion time of platelet plug formation induced by irradiation of mesenteric venules of fluorescein sodium-pretreated mice. In contrast, trigramin (10-20 mg/kg) and GRGDS (500 and 1000 mg/kg) showed no significant effect. These results suggest that triflavin has an effective antiplatelet effect in vivo and this peptide may be a useful therapeutic agent for arterial thrombosis.
原文 | 英語 |
---|---|
頁(從 - 到) | 231-238 |
頁數 | 8 |
期刊 | European Journal of Pharmacology |
卷 | 294 |
發行號 | 1 |
DOIs | |
出版狀態 | 已發佈 - 十二月 27 1995 |
指紋
ASJC Scopus subject areas
- Cellular and Molecular Neuroscience
- Pharmacology
引用此文
Triflavin, an Arg-Gly-Asp-containing peptide, prevents platelet plug formation in in vivo experiments. / Sheu, Joen Rong; Yen, Mao Hsiung; Peng, Hui Chin; Chang, Mei Chi; Huang, Tur Fu.
於: European Journal of Pharmacology, 卷 294, 編號 1, 27.12.1995, p. 231-238.研究成果: 雜誌貢獻 › 文章
}
TY - JOUR
T1 - Triflavin, an Arg-Gly-Asp-containing peptide, prevents platelet plug formation in in vivo experiments
AU - Sheu, Joen Rong
AU - Yen, Mao Hsiung
AU - Peng, Hui Chin
AU - Chang, Mei Chi
AU - Huang, Tur Fu
PY - 1995/12/27
Y1 - 1995/12/27
N2 - Triflavin, an Arg-Gly-Asp-containing peptide from Trimeresurus flauoviridis snake venom (M1, of 7500 Da) inhibits platelet aggregation through the blockade of fibrinogen binding to activated platelets. The present study demonstrated that the intravenous injection of triflavin (0.1 and 0.25 mg/kg) significantly prolonged the bleeding time about 1.8- to 2.4-fold as compared with control (normal saline) of severed mesenteric arteries in rats, whereas the injection of Gly-Arg-Gly-Asp-Ser (GRGDS) (2-8 mg/kg) failed to increase the bleeding time in this model. Continuous infusion of triflavin (0.08 mg/kg/min) significantly increased the bleeding time about 2.6-fold, and the bleeding time returned to normal within 20 min after the cessation of triflavin infusion. Triflavin (10-20 mg/kg) significantly prolonged the occlusion time of platelet plug formation induced by irradiation of mesenteric venules of fluorescein sodium-pretreated mice. In contrast, trigramin (10-20 mg/kg) and GRGDS (500 and 1000 mg/kg) showed no significant effect. These results suggest that triflavin has an effective antiplatelet effect in vivo and this peptide may be a useful therapeutic agent for arterial thrombosis.
AB - Triflavin, an Arg-Gly-Asp-containing peptide from Trimeresurus flauoviridis snake venom (M1, of 7500 Da) inhibits platelet aggregation through the blockade of fibrinogen binding to activated platelets. The present study demonstrated that the intravenous injection of triflavin (0.1 and 0.25 mg/kg) significantly prolonged the bleeding time about 1.8- to 2.4-fold as compared with control (normal saline) of severed mesenteric arteries in rats, whereas the injection of Gly-Arg-Gly-Asp-Ser (GRGDS) (2-8 mg/kg) failed to increase the bleeding time in this model. Continuous infusion of triflavin (0.08 mg/kg/min) significantly increased the bleeding time about 2.6-fold, and the bleeding time returned to normal within 20 min after the cessation of triflavin infusion. Triflavin (10-20 mg/kg) significantly prolonged the occlusion time of platelet plug formation induced by irradiation of mesenteric venules of fluorescein sodium-pretreated mice. In contrast, trigramin (10-20 mg/kg) and GRGDS (500 and 1000 mg/kg) showed no significant effect. These results suggest that triflavin has an effective antiplatelet effect in vivo and this peptide may be a useful therapeutic agent for arterial thrombosis.
KW - Bleeding time
KW - Fibrinogen receptor antagonist
KW - Mesenteric artery
KW - RGD (Arg-Gly-Asp)-containing peptide
KW - Thrombosis
KW - Triflavin
UR - http://www.scopus.com/inward/record.url?scp=0029610590&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029610590&partnerID=8YFLogxK
U2 - 10.1016/0014-2999(95)00530-7
DO - 10.1016/0014-2999(95)00530-7
M3 - Article
C2 - 8788436
AN - SCOPUS:0029610590
VL - 294
SP - 231
EP - 238
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
SN - 0014-2999
IS - 1
ER -